Kazakhstan tests groundbreaking allergy drug PollenVax in Phase II trials

Scientists in Kazakhstan have begun Phase II clinical trials for a new immunotherapeutic drug called PollenVax. The treatment targets wormwood pollen allergies, a widespread issue affecting many residents in the country. The project represents a major step forward for the nation’s biopharmaceutical industry. Wormwood pollen allergy is a common seasonal problem in Kazakhstan, with about 30% of allergy cases linked to this pollen. In Almaty, the pollination season runs from July to November, causing allergic rhinitis in thousands of people. Current treatments only provide temporary relief rather than addressing the underlying cause.

Phase I trials for PollenVax involved 30 volunteers and confirmed its safety and tolerability. Regulatory approval has now been granted for Phase II trials, which will include 138 patients aged 18 to 65 with confirmed wormwood pollen-induced allergic rhinitis. The trial is a randomized, double-blind, placebo-controlled study lasting up to 180 days.

PollenVax offers a shorter treatment course, requiring just four weekly subcutaneous injections. The drug is produced by OtarBioPharm LLP, which follows international GMP standards. The launch of Phase II trials highlights the potential of domestic science to address pressing healthcare challenges. PollenVax could provide a more effective solution for allergy sufferers in Kazakhstan. The project also strengthens the country’s ability to develop innovative biopharmaceutical treatments.